Tweets
ACR RISE registry study looked at Rx of 3276 Sarcoidosis pts from 184 rheum practices finds 59.3% rx w/ steroids (24% prolonged steroids). and 12.1 Rx w/ biologics or tsDMARDs, mostly TNFi (inflx). But wide practice-level variations in Rx https://t.co/95CEDai2uN
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 5 months ago
MMWR study of shows 2 dose mRNA COVID vax during pregnancy was 61% effective preventing infant COVID. Among 176 infants hosp w/ COVID-19, 84% were born to mothers who were not vaccinated during pregnancy.https://t.co/mWgHHcL05u
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 5 months ago
Saphnelo (anifrolumab) has been approved in the European Union as an add-on therapy for the treatment of adult with moderate to severe, active, autoantibody-positive systemic lupus erythematosus (SLE), despite receiving standard therapy.https://t.co/fdZAFFDrYW
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 5 months ago
Study of 25/306 SLE patients (8.2%) who developed 29 episodes of Pulmonary Hemorrhage (PH). 1st manifestation . PH assoc w/ Renal dz, high SLE activity during PH; PH mortality w/ Renal failure & mech ventilation. https://t.co/ydJkgf5BFB
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 5 months ago
We have an exciting agenda for #RNL2022, with topics ranging from Psoriatic Disease for Rheumatologists to Advances in Psoriasis Management and speakers from around the world, including Dr. Bruce Strober.
Register Today!
https://t.co/VZ2hmxAmDw https://t.co/AJbSLNXDql
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 5 months ago
Dr Virginia Steen at #RWCS2022. On scleroderma lung Dz that worsens outcomes https://t.co/n7IV8UVI2N https://t.co/kLmiKiseur
Dr. John Cush @RheumNow ( View Tweet )
4 years 5 months ago
Rheumatoid Arthritis Nonadherence is Multifactorial
A 6-month prospective cohort study of RA patients shows NA to vary according to drug type and be related to psychological, communicational, logistic, sociodemographic or clinical factors.
https://t.co/FWamPS2fTQ https://t.co/EtoStfdTsI
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 5 months ago
Dr Eric Ruderman presents on paraneoplastic syndromes. Many autoantibodies have been possibly implicated. #RWCS2022 https://t.co/n7IV8UVI2N https://t.co/xx54hAKY3C
Dr. John Cush @RheumNow ( View Tweet )
4 years 5 months ago
1st approved Rx for neuromyelitis optical (Device syndr). Eculizumab, C5a inhibitor, weird effective at preventing relapses of NMO #RWCS2022 https://t.co/n7IV8UVI2N https://t.co/a6LyTi3LXL
Dr. John Cush @RheumNow ( View Tweet )
4 years 5 months ago
Dr Eric Ruderman presents treatment of Stiff Man syndrome why muscle relaxants, benzos, IVIG?? Poor outcomes nevertheless #RWCS2022 https://t.co/n7IV8UVI2N https://t.co/xDXJCM34aO
Dr. John Cush @RheumNow ( View Tweet )
4 years 5 months ago
Dr Eric Ruderman presents on rare Stiff Man syndrome at #RWCS2022 https://t.co/n7IV8UVI2N
Dr. John Cush @RheumNow ( View Tweet )
4 years 5 months ago
EMA has posted its intent to review the safety of JAK inhibitors used to treat several chronic inflammatory disorders (RA, PsA, JIA, AS, UC, atopic dermatitis) based on the release of the Pfizer tofacitinib A3921133 study https://t.co/loG7zWBWHs
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 5 months ago
